• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Apimeds Pharmaceuticals US, Inc. Common Stock (NY:APUS)

    1.510 +0.140 (+10.22%)
    Official Closing Price Updated: 4:10 PM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Apimeds Pharmaceuticals US, Inc. Common Stock

    News headline image
    Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
    From The Rosen Law Firm, P.A.
    Via Business Wire
    MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
    Via CryptoCurrencyWire
    Topics Artificial Intelligence Economy
    MindWave Innovations Inc. (NYSE American: APUS) Is ‘One to Watch’
    Via Investor Brand Network
    Topics Artificial Intelligence Economy
    News headline image
    Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
    From Apimeds Pharmaceuticals US, Inc.
    Via GlobeNewswire
    News headline image
    Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)
    From Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc.
    Via Business Wire
    News headline image
    Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    News headline image
    Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
    From Apimeds Pharmaceuticals US, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.